Vertex Pharma stock (US92532F1003): Valuation stays in focus after a fresh move

Vertex Pharma traded higher in New York on 05/29/2026 as investors weighed a new Health Canada filing and the stock's latest valuation metrics on Nasdaq.

Vertex Pharma shares were quoted at USD 446.50 on 05/29/2026 on Nasdaq, after trading between USD 434.08 and USD 449.29 during the session, according to Robinhood's market data for VRTX. The move keeps the US-listed biotech in focus for investors in the United States, where the company remains one of the better-known large-cap names in the Nasdaq healthcare group.

A separate filing-related development added to the day's trading tone: a report on 05/29/2026 said Health Canada accepted a new drug submission for Suzetrigine, giving the stock another home-country relevant catalyst for US investors following the company's regulatory path in North America. MarketBeat's latest instant-alert page also cited a consensus rating of Moderate Buy and an average target price of USD 555.91, underscoring that the stock is still being tracked closely by sell-side and aggregator models as of 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Vertex Pharma
• Sector/industry: Biotechnology
• Headquarters/country: Boston, United States
• Core markets: United States, Europe, and other international markets
• Key revenue drivers: Commercialized medicines and pipeline advances in serious disease areas
• Home exchange/listing venue: Nasdaq (VRTX)
• Trading currency: USD

Vertex Pharma: core business model

Vertex Pharma develops, manufactures, and commercializes medicines aimed at serious diseases, with revenue tied mainly to marketed therapies and progress on pipeline assets.

Valuation metrics and multiples for Vertex Pharma

Vertex Pharma's latest widely cited valuation markers place the stock at a P/E ratio of 25.92, with a market capitalization of USD 113.76 billion and a session high-low range of USD 449.29 to USD 434.08 on 05/29/2026, according to Robinhood's market quote page for VRTX. Those figures frame why the stock remains a valuation story as well as a pipeline story on Nasdaq in the United States.

According to MarketBeat as of 05/29/2026, the consensus across analysts is Moderate Buy with an average price target of USD 555.91, based on its stock alert coverage of Vertex Pharmaceuticals. That consensus sits well above the latest quoted level, but the article does not assume any direction beyond the published figures.

Conclusion

Vertex Pharma remains in the market spotlight because the latest Nasdaq quote, valuation profile, and analyst consensus all point to a stock that is still actively repriced by investors in the United States. The Health Canada submission update adds a separate regulatory angle that may matter for sentiment, even as the Friday valuation module keeps attention on the numbers already in the market.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.